Skip to main content
IntoCell, Inc. logo

IntoCell, Inc. — Investor Relations & Filings

Ticker · 287840 ISIN · KR7287840003 KO Professional, scientific and technical activities
Open in API
Filings indexed 48 across all filing types
Latest filing 2025-05-12 Capital/Financing Update
Country KR South Korea
Listing KO 287840

About IntoCell, Inc.

https://intocell.com/

IntoCell, Inc. is a biotechnology company specializing in the research and development of platform technologies for Antibody-Drug Conjugates (ADCs). The company's core focus is on creating novel biopharmaceuticals, primarily for oncology applications. IntoCell develops proprietary technologies, including its OHPAS™ linker and Payload Modification Technology (PMT™), which are designed to improve the stability, efficacy, and safety of ADC therapeutics. The company advances its own drug pipeline and also collaborates with other pharmaceutical companies through technology transfer and partnership agreements to commercialize its ADC platforms.

Recent filings

Filing Released Lang Actions
[기재정정]투자설명서
Capital/Financing Update Classification · 1% confidence The document is a '정정신고서' (Amendment Report) for an '투자설명서' (Investment Prospectus) filed by Intocell Co., Ltd. It details changes to the public offering price, total offering amount, and allocation ratios for institutional and general investors. In the context of financial filings, an amendment to a prospectus related to an IPO or public offering is classified as a Regulatory Filing (RNS) or a specific capital-related filing. Since it is a formal regulatory amendment regarding the offering process and pricing, it fits best under the Regulatory Filings category.
2025-05-12 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It is a formal regulatory filing submitted to the Financial Services Commission (금융위원회) in South Korea. It details the amendment of a previous filing (정정신고) concerning the purpose of funds, share issuance price, and other terms related to a capital increase. This falls under the category of share issuance and capital changes.
2025-05-12 Korean
투자설명서
Capital/Financing Update Classification · 1% confidence The document is a '투자설명서' (Investment Prospectus) for a company named '주식회사 인투셀' (IntoCell Co., Ltd.). It contains detailed information regarding a public offering of shares, including the number of shares, offering price, subscription period, and extensive 'Risk Factors' (핵심투자위험) related to the business, industry, and financial status. This document is a formal regulatory filing required for an IPO (Initial Public Offering) in South Korea. Among the provided categories, 'Proxy Solicitation & Information Statement' (PSI) is the closest fit for a prospectus document used to solicit investment and provide detailed company information to potential shareholders, as it serves as a formal disclosure statement.
2025-05-07 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed by '주식회사 인투셀' (Intocell Co., Ltd.) with the Financial Supervisory Service (DART). It explicitly mentions multiple amendments ('정정') to the original filing, providing detailed financial justifications, valuation methodologies (PER calculations), and risk factors related to a public offering. This is a formal regulatory filing required for capital raising activities, which falls under the 'Regulatory Filings' category as it is a primary registration document for securities.
2025-05-02 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by '주식회사 인투셀' on April 10, 2025. It details specific corrections and additions made to a previously submitted securities registration statement (originally filed on March 24, 2025). In the context of financial filings, a Securities Registration Statement (and its amendments) is a primary regulatory document required for public offerings or listings. Since it does not fit into the specific categories like 'Annual Report' or 'Earnings Release', and is a formal regulatory filing submitted to the financial authorities, it is classified as a Regulatory Filing.
2025-04-10 Korean
사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 10th fiscal year (2024) of 'IntoCell, Inc.'. It contains detailed financial information, business operations, management structure, and capital changes. This is a comprehensive annual filing submitted to the Financial Services Commission and the Korea Exchange, which corresponds to the '10-K' (Annual Report) category in the provided schema. FY 2024
2025-03-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.